Copyright
©The Author(s) 2018.
World J Hepatol. Sep 27, 2018; 10(9): 571-584
Published online Sep 27, 2018. doi: 10.4254/wjh.v10.i9.571
Published online Sep 27, 2018. doi: 10.4254/wjh.v10.i9.571
Age diagnosed as HCC | Sex | Etiology | Child-Pugh | Tumor stage1 | Previous treatment | Maximum tumor size (mm) | Vascular invasion1 | Regimen | Therapeutic effect | AFP (ng/mL) | DCP (mAU/mL) | HCC recurrence | Prognosis | Cause of death |
67 | Male | HCV | A (5) | IVA | None | 110 | Vp4, Vv0 | Low-dose FP | CR | 120700 | 260 | 62 mo | 151 mo (dead) | Hepatic failure |
66 | Male | HCV | A (5) | III | None | 50 | Vp0, Vv0 | Low-dose FP + IV | CR | 6.4 | 2970 | None | 176 mo (dead) | Larynx cancer |
44 | Male | HBV | B (7) | III | None | 150 | Vp3, Vv3 | Low-dose FP + IV + Peg IFN | CR | 7145 | 233640 | None | 148 mo (alive2) | - |
- Citation: Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Fujisawa K, Matsumoto T, Hidaka I, Marumoto Y, Ishikawa T, Yamamoto N, Suehiro Y, Takami T, Sakaida I. Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy. World J Hepatol 2018; 10(9): 571-584
- URL: https://www.wjgnet.com/1948-5182/full/v10/i9/571.htm
- DOI: https://dx.doi.org/10.4254/wjh.v10.i9.571